Acute Agitation and Aggression Treatment Market Size Report, 2022-2030
The global Acute Agitation and Aggression Treatment market gathered revenue around USD 5.2 billion in 2021 and market is set to grow USD 8.2 billion by the end of 2030 and is estimated to expand at a modest CAGR of 6.4% during the prediction period 2022 to 2030.
Growth Factors:
Agitation can be defined as excessive motor or verbal behavior, which can further escalate to aggression. Physical agitation and aggression are manifested in the form of throwing objects toward people, and verbal agitation and aggression manifests as abuses and threats. Acute agitation and aggression are the common symptoms of mental illnesses such as schizophrenia, dementia, bipolar disorder, alcohol withdrawal, and depression.
Changing attitude toward diagnosis of agitation and aggression among mentally ill patients and rise in awareness about treatments is the key factor projected to drive the global acute agitation and aggression treatment market during the forecast period.
North America held major share of the global acute agitation and aggression treatment market in 2020. Focus on spreading awareness about treatment related to agitation and aggression among people, increase in economic burden of mental illness, well-established healthcare infrastructure, presence of leading players, and rise in focus of these players on research & development boost the growth of the market in North America.
The acute agitation and aggression treatment market in Asia Pacific is expected to expand at a CAGR of 6.9% from 2022 to 2030. Growth of the market in the region can be attributed to increase in the geriatric population, rise in prevalence of mental illnesses such as schizophrenia & bipolar disorder, and focus of market players on India and Japan to exploit opportunities in the emerging markets.
Report Scope of the Acute Agitation and Aggression Treatment Market
|
Report Coverage |
Details |
|
Market Size |
US$ 8.2 Billion by 2030 |
|
Growth Rate |
CAGR of 6.4% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Treatment Approach, Indication, Route of Administration, End-user and Region, |
|
Companies Mentioned |
Eli Lilly and Company, Pfizer, Inc., GlaxoSmithKline, Otsuka Holdings Co., Ltd., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, and H. Lundbeck A/S, Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Bausch Health Companies, Inc., Apotex, Inc., and Aurobindo Pharma. |
Increase in Incidence of Dementia in Geriatric Population to Drive Market
Dementia is a condition, which results in decline in memory and other cognitive functions, affecting daily functioning. This condition is more common among the geriatric population. According to the WHO, dementia is expected to affect 82 million people in 2030 and 152 million people in 2050 globally. According to Alzheimer’s Association Report, an estimated 5.8 million people in the U.S. aged 65 and over lived with Alzheimer's disease in 2020. The number of people aged 65 and older with Alzheimer’s dementia is projected to reach 13.8 million by 2050 owing to increase in the geriatric population. Agitation and aggression are considered the most common symptoms experienced by dementia patients. Therefore, increase in incidence of dementia among the geriatric population is likely to boost the growth of the global acute agitation and aggression treatment during the forecast period.
Pharmacologic Approaches (Drugs) Held Major Share of Global Market
In terms of treatment approach, the global acute agitation and aggression treatment market has been classified into behavioral approaches, environmental interventions, and pharmacologic approaches (drugs). The pharmacologic approaches (drugs) segment has been split into lorazepam, chlorpromazine, quetiapine, droperidol, olanzapine, ziprasidone, and others. The pharmacologic approaches (drugs) segment dominated the global market in 2020. In emergency care settings, pharmacological approach reduces agitation or aggressive behavior without causing excessive sedation, and ideally avoid invasive administration routes. Traditionally, the following classes of medications have been used to treat agitation: first-generation antipsychotics (FGAs), benzodiazepines (BZDs), and second-generation antipsychotics (SGAs). The growth of the segment can be attributed to the effectiveness of these drugs in controlling agitation and aggression.
Preference for Oral Route for Acute Agitation and Aggression Treatment
Based on route of administration, the global acute agitation and aggression treatment market has been categorized into oral, intramuscular, and others. The oral segment dominated the global acute agitation and aggression treatment market in 2020, and the trend is anticipated to continue during the forecast period. The growth of the segment can be attributed to the preference for oral medications for the treatment of agitation and aggression
Schizophrenia Dominated Global Market
In terms of indication, the global acute agitation and aggression treatment market has been segregated into schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation & aggression, alcohol withdrawal, and others. The schizophrenia segment accounted for major share of the global acute agitation and aggression treatment market in 2020. The segment’s dominance can be attributed to the availability of approved drugs for the treatment of agitation in schizophrenia.
Hospitals & Ambulatory Surgical Centers to be Major End-user
Based on end-user, the global acute agitation and aggression treatment market has been divided into hospitals & ambulatory surgical centers, psychiatric care facilities, and others. The hospitals & ambulatory surgical centers segment accounted for a major share of the global acute agitation and aggression treatment market in 2020. The segment is projected to be driven by increase in mental illness patient visits for emergency treatment.
North America to Dominate Global Market; Asia Pacific to Offer Significant Opportunities
In terms of region, the global acute agitation and aggression treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a prominent share of the global acute agitation and aggression treatment market during the forecast period. Significant investments by the market players in research & development leading to a strong pipeline of drugs for the treatment of agitation in mental illness are the major factors driving the market in North America.
The market in Europe is anticipated to expand at a high CAGR in the near future, owing to significant number of non-government organizations focused on spreading awareness about the treatment for mental illness. For instance, the Alzheimer’s Society in the U.K., a charity organization that creates campaigns to spread awareness about the signs of agitation and aggression in Alzheimer’s, funds research efforts to find a cure for the disease in the region.
The acute agitation and aggression treatment market in Asia Pacific is expected to grow at a rapid pace in the near future. This can be attributed to increase in the geriatric population, rise in prevalence of mental illness such as schizophrenia and bipolar disorder, and focus of market players on India and Japan to exploit opportunities in the emerging markets.
Some of the prominent players in the Acute Agitation and Aggression Treatment Market include:
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
Acute Agitation and Aggression Treatment Market, by Treatment Approach
Acute Agitation and Aggression Treatment Market, by Indication
Acute Agitation and Aggression Treatment Market, by Route of Administration
Acute Agitation and Aggression Treatment Market, by End-user
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Acute Agitation and Aggression Treatment Market Study:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Agitation and Aggression Treatment Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Patient journey Analysis
5.3. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
5.4. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.5. Pros and Cons of current Treatment for Acute Agitation and Aggression
5.6. Technological Advancements
6. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Treatment Approach
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment Approach, 2017–2030
6.3.1. Behavioral Approaches
6.3.2. Environmental Interventions
6.3.3. Pharmacologic Approaches (Drugs)
6.3.3.1. Lorazepam
6.3.3.2. Chlorpromazine
6.3.3.3. Quetiapine
6.3.3.4. Droperidol
6.3.3.5. Olanzapine
6.3.3.6. Ziprasidone
6.3.3.7. Others
6.4. Market Attractiveness Analysis, by Treatment Approach
7. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Indication, 2017–2030
7.3.1. Schizophrenia
7.3.2. Dementia
7.3.3. Bipolar Disorder
7.3.4. Depression
7.3.5. Drug-induced Agitation and Aggression
7.3.6. Alcohol Withdrawal
7.3.7. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Route of Administration, 2017–2030
8.3.1. Oral
8.3.2. Intramuscular
8.3.3. Others
8.4. Market Attractiveness Analysis, by Route of Administration
9. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2030
9.3.1. Hospitals & Ambulatory Surgical Centers
9.3.2. Psychiatric Care Facilities
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Acute Agitation and Aggression Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Country/Region
11. North America Acute Agitation and Aggression Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Approach, 2017–2030
11.2.1. Behavioral Approaches
11.2.2. Environmental Interventions
11.2.3. Pharmacologic Approaches (Drugs)
11.2.3.1. Lorazepam
11.2.3.2. Chlorpromazine
11.2.3.3. Quetiapine
11.2.3.4. Droperidol
11.2.3.5. Olanzapine
11.2.4. Ziprasidone
11.2.4.1. Others
11.3. Market Value Forecast, by Indication, 2017–2030
11.3.1. Schizophrenia
11.3.2. Dementia
11.3.3. Bipolar Disorder
11.3.4. Depression
11.3.5. Drug-induced Agitation and Aggression
11.3.6. Alcohol Withdrawal
11.3.7. Others
11.4. Market Value Forecast, by Route of Administration, 2017–2030
11.4.1. Oral
11.4.2. Intramuscular
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2017–2030
11.5.1. Hospitals & Ambulatory Surgical Centers
11.5.2. Psychiatric Care Facilities
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017–2030
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Treatment Approach
11.7.2. By Indication
11.7.3. By Route of Administration
11.7.4. By End-user
11.7.5. By Country
12. Europe Acute Agitation and Aggression Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Approach, 2017–2030
12.2.1. Behavioral Approaches
12.2.2. Environmental Interventions
12.2.3. Pharmacologic Approaches (Drugs)
12.2.3.1. Lorazepam
12.2.3.2. Chlorpromazine
12.2.3.3. Quetiapine
12.2.3.4. Droperidol
12.2.3.5. Olanzapine
12.2.3.6. Ziprasidone
12.2.3.7. Others
12.3. Market Value Forecast, by Indication , 2017–2030
12.3.1. Schizophrenia
12.3.2. Dementia
12.3.3. Bipolar Disorder
12.3.4. Depression
12.3.5. Drug-induced Agitation and Aggression
12.3.6. Alcohol Withdrawal
12.3.7. Others
12.4. Market Value Forecast, by Route of Administration, 2017–2030
12.4.1. Oral
12.4.2. Intramuscular
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2017–2030
12.5.1. Hospitals & Ambulatory Surgical Centers
12.5.2. Psychiatric Care Facilities
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2030
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Treatment Approach
12.7.2. By Indication
12.7.3. By Route of Administration
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Acute Agitation and Aggression Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Approach, 2017–2030
13.2.1. Behavioral Approaches
13.2.2. Environmental Interventions
13.2.3. Pharmacologic Approaches (Drugs)
13.2.3.1. Lorazepam
13.2.3.2. Chlorpromazine
13.2.3.3. Quetiapine
13.2.3.4. Droperidol
13.2.3.5. Olanzapine
13.2.3.6. Ziprasidone
13.2.3.7. Others
13.3. Market Value Forecast, by Indication, 2017–2030
13.3.1. Schizophrenia
13.3.2. Dementia
13.3.3. Bipolar Disorder
13.3.4. Depression
13.3.5. Drug-induced Agitation and Aggression
13.3.6. Alcohol Withdrawal
13.3.7. Others
13.4. Market Value Forecast, by Route of Administration , 2017–2030
13.4.1. Oral
13.4.2. Intramuscular
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2017–2030
13.5.1. Hospitals & Ambulatory Surgical Centers
13.5.2. Psychiatric Care Facilities
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2030
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Treatment Approach
13.7.2. By Indication
13.7.3. By Route of Administration
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Acute Agitation and Aggression Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Approach, 2017–2030
14.2.1. Behavioral Approaches
14.2.2. Environmental Interventions
14.2.3. Pharmacologic Approaches (Drugs)
14.2.3.1. Lorazepam
14.2.3.2. Chlorpromazine
14.2.3.3. Quetiapine
14.2.3.4. Droperidol
14.2.3.5. Olanzapine
14.2.4. Ziprasidone
14.2.4.1. Others
14.3. Market Value Forecast, by Indication , 2017–2030
14.3.1. Schizophrenia
14.3.2. Dementia
14.3.3. Bipolar Disorder
14.3.4. Depression
14.3.5. Drug-induced Agitation and Aggression
14.3.6. Alcohol Withdrawal
14.3.7. Others
14.4. Market Value Forecast, by Route of Administration , 2017–2030
14.4.1. Oral
14.4.2. Intramuscular
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2017–2030
14.5.1. Hospitals & Ambulatory Surgical Centers
14.5.2. Psychiatric Care Facilities
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2030
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Treatment Approach
14.7.2. By Indication
14.7.3. By Route of Administration
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Acute Agitation and Aggression Treatment Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Approach, 2017–2030
15.2.1. Behavioral Approaches
15.2.2. Environmental Interventions
15.2.3. Pharmacologic Approaches (Drugs)
15.2.3.1. Lorazepam
15.2.3.2. Chlorpromazine
15.2.3.3. Quetiapine
15.2.3.4. Droperidol
15.2.3.5. Olanzapine
15.2.4. Ziprasidone
15.2.4.1. Others
15.3. Market Value Forecast, by Indication, 2017–2030
15.3.1. Schizophrenia
15.3.2. Dementia
15.3.3. Bipolar Disorder
15.3.4. Depression
15.3.5. Drug-induced Agitation and Aggression
15.3.6. Alcohol Withdrawal
15.3.7. Others
15.4. Market Value Forecast, by Route of Administration, 2017–2030
15.4.1. Oral
15.4.2. Intramuscular
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2017–2030
15.5.1. Hospitals and Ambulatory Surgical Centers
15.5.2. Psychiatric Care Facilities
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2030
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Treatment Approach
15.7.2. By Indication
15.7.3. By Route of Administration
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Company Profiles
16.2.1. Eli Lilly and Company
16.2.1.1. Company Overview
16.2.1.2. Company Financials
16.2.1.3. Growth Strategies
16.2.1.4. SWOT Analysis
16.2.2. Pfizer, Inc.
16.2.2.1. Company Overview
16.2.2.2. Company Financials
16.2.2.3. Growth Strategies
16.2.2.4. SWOT Analysis
16.2.3. Otsuka Holdings
16.2.3.1. Company Overview
16.2.3.2. Company Financials
16.2.3.3. Growth Strategies
16.2.3.4. SWOT Analysis
16.2.4. GlaxoSmithKline
16.2.4.1. Company Overview
16.2.4.2. Company Financials
16.2.4.3. Growth Strategies
16.2.4.4. SWOT Analysis
16.2.5. H. Lundbeck A/S
16.2.5.1. Company Overview
16.2.5.2. Company Financials
16.2.5.3. Growth Strategies
16.2.5.4. SWOT Analysis
16.2.6. Johnson & Johnson
16.2.6.1. Company Overview
16.2.6.2. Company Financials
16.2.6.3. Growth Strategies
16.2.6.4. SWOT Analysis
16.2.7. Teva Pharmaceutical Industries Ltd.
16.2.7.1. Company Overview
16.2.7.2. Company Financials
16.2.7.3. Growth Strategies
16.2.7.4. SWOT Analysis
16.2.8. Amneal Pharmaceuticals LLC
16.2.8.1. Company Overview
16.2.8.2. Company Financials
16.2.8.3. Growth Strategies
16.2.8.4. SWOT Analysis
16.2.9. Sun Pharmaceutical Industries Ltd.
16.2.9.1. Company Overview
16.2.9.2. Company Financials
16.2.9.3. Growth Strategies
16.2.9.4. SWOT Analysis
16.2.10. F. Hoffmann-La Roche Ltd.
16.2.10.1. Company Overview
16.2.10.2. Company Financials
16.2.10.3. Growth Strategies
16.2.10.4. SWOT Analysis
16.2.11. Bausch Health Companies, Inc.
16.2.11.1. Company Overview
16.2.11.2. Company Financials
16.2.11.3. Growth Strategies
16.2.11.4. SWOT Analysis
16.2.12. Apotex, Inc.
16.2.12.1. Company Overview
16.2.12.2. Company Financials
16.2.12.3. Growth Strategies
16.2.12.4. SWOT Analysis
16.2.13. Aurobindo Pharma
16.2.13.1. Company Overview
16.2.13.2. Company Financials
16.2.13.3. Growth Strategies
16.2.13.4. SWOT Analysis
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers